Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Change in Account Payables (2022 - 2025)

Bioregenx's Change in Account Payables history spans 4 years, with the latest figure at $156339.0 for Q4 2025.

  • Quarterly results put Change in Account Payables at $156339.0 for Q4 2025, up 262.39% from a year ago — trailing twelve months through Dec 2025 was $188512.0 (up 2178.92% YoY), and the annual figure for FY2025 was $188512.0, up 2178.92%.
  • Change in Account Payables for Q4 2025 was $156339.0 at Bioregenx, up from -$109148.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $156339.0 in Q4 2025 to a low of -$295866.0 in Q3 2023.
  • The 4-year median for Change in Account Payables is $4635.5 (2022), against an average of -$4323.3.
  • Peak annual rise in Change in Account Payables hit 3914.29% in 2023, while the deepest fall reached 10158.88% in 2023.
  • Year by year, Change in Account Payables stood at $2355.0 in 2022, then soared by 3515.03% to $85134.0 in 2023, then plummeted by 49.33% to $43141.0 in 2024, then surged by 262.39% to $156339.0 in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at $156339.0, -$109148.0, and $141056.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.